MilliporeSigma
  • Home
  • Search Results
  • Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance.

Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance.

American journal of cancer research (2015-01-30)
Lin-Hai Yan, Wei-Yuan Wei, Wen-Long Cao, Xiao-Shi Zhang, Yu-Bo Xie, Qiang Xiao
ABSTRACT

Modulator of multidrug resistance (MDR) gene is a direct transcriptional target of CDX2. However, we still speculate whether CDX2 affects MDR through other ways. In this study, a cisplatin-resistant (SGC7901/DDP) and a 5-fluoro-2, 4(1h,3h)pyrimidinedione-resistant (BGC823/5-FU) gastric cancer cell line with stable overexpression of CDX2 were established. The influence of overexpression of CDX2 on MDR was assessed by measuring IC50 of SGC7901/DDP and BGC823/5-FU cells to cisplatin, doxorubicin, and 5-fluorouracil, rate of doxorubicin efflux, apoptosis, and cell cycle progression detected by flow cytometry. In addition, we determined the in vivo effects of CDX2-overexpression lentiviral vector (LV-CDX2-GFP) on tumor size, and apoptotic cells in tumor tissues were detected by deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling and hematoxylin and eosin staining. Results showed that LV-CDX2-GFP led to up-regulation of CDX2 mRNA and protein expression. It significantly inhibited the sensitivity of SGC7901/DDP and BGC823/5-FU cells to cisplatin, doxorubicin, and 5-fluorouracil. Flow cytometry confirmed that the percentage of apoptotic cells decreased after CDX2 up-regulation. This notion was further supported by the observation that up-regulation of CDX2 blocked entry into the M-phase of the cell cycle. Furthermore, up-regulation of CDX2 significantly decreased intracellular accumulation of doxorubicin. In molecular studies, quantitative reverse-transcriptase real-time polymerase chain reaction and western blotting revealed that CDX2 up-regulation could suppress expression of Caspase-3, Caspase-9 and PTEN, and increased the expression of MDR1, MRP, mTOR, HIF-1α.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
cis-Diammineplatinum(II) dichloride, crystalline
Sigma-Aldrich
trans-Platinum(II)diammine dichloride
Cisplatin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
DL-Glyceraldehyde 3-phosphate solution, 45-55 mg/mL in H2O
Sigma-Aldrich
cis-Diamineplatinum(II) dichloride, ≥99.9% trace metals basis
Sigma-Aldrich
Fluorouracil, meets USP testing specifications
Sigma-Aldrich
5-Fluorouracil, ≥99% (HPLC), powder
Fluorouracil, European Pharmacopoeia (EP) Reference Standard
Supelco
Fluorouracil, Pharmaceutical Secondary Standard; Certified Reference Material
Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard
USP
Fluorouracil, United States Pharmacopeia (USP) Reference Standard
USP
Transplatin, United States Pharmacopeia (USP) Reference Standard
Supelco
5-Fluorouracil, analytical standard